vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. 詳細を表示
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER PR Newswire WESTON, Fla., Dec. 9, 2024 WESTON, Fla., Dec. 9...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.3223 | 2.43245283019 | 13.25 | 14.33 | 13.15 | 10660 | 13.67399053 | CS |
4 | -3.2977 | -19.5477178423 | 16.87 | 18.37 | 13.15 | 16213 | 15.96376815 | CS |
12 | -0.2977 | -2.14635904831 | 13.87 | 18.37 | 12.62 | 31284 | 15.18992581 | CS |
26 | -4.0677 | -23.0595238095 | 17.64 | 24.9 | 12.1201 | 30403 | 16.13044486 | CS |
52 | 2.0223 | 17.5090909091 | 11.55 | 30.99 | 7.38 | 35652 | 16.25080271 | CS |
156 | -27.2277 | -66.7345588235 | 40.8 | 56 | 7.38 | 175085 | 29.12465265 | CS |
260 | -54.8277 | -80.1574561404 | 68.4 | 205.2 | 7.38 | 896708 | 99.55938861 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約